Neurogene (NGNE) Income towards Parent Company (2013 - 2026)
Neurogene posted quarterly Income towards Parent Company of -$31.1 million for Q1 2026, down 36.9% year-on-year from -$49.3 million in Q1 2025, and down 26.08% on a QoQ basis from -$24.7 million in Q4 2025.
Neurogene (NGNE) has 14 years of Income towards Parent Company data on file, last reported at -$31.1 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 36.9% year-over-year to -$31.1 million; the trailing twelve-month figure through Mar 2026 stood at -$100.1 million (down 23.67% YoY), and the FY2025 full-year result was -$91.8 million, down 23.78% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$31.1 million, down from -$24.7 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$11.7 million in Q4 2022 and bottomed at -$31.1 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$16.5 million (2024), against an average of -$18.0 million.
- The widest annual swing landed in 2023, when Income towards Parent Company rose 25.3%; it then plunged 57.15% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$11.7 million in 2022, then dropped by 19.69% to -$14.0 million in 2023, then sank by 37.76% to -$19.2 million in 2024, then declined by 28.17% to -$24.7 million in 2025, then declined by 26.08% to -$31.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$31.1 million (Q1 2026), -$24.7 million (Q4 2025), and -$21.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Neurogene | 632.14 Mn | 632.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.10 Mn |
| Dec 31, 2025 | -24.67 Mn |
| Sep 30, 2025 | -21.10 Mn |
| Jun 30, 2025 | -23.23 Mn |
| Mar 31, 2025 | -22.72 Mn |
| Dec 31, 2024 | -19.24 Mn |
| Sep 30, 2024 | -20.34 Mn |
| Jun 30, 2024 | -18.63 Mn |
| Mar 31, 2024 | -16.46 Mn |
| Dec 31, 2023 | -13.97 Mn |
| Sep 30, 2023 | -14.57 Mn |
| Jun 30, 2023 | -11.86 Mn |
| Mar 31, 2023 | -12.26 Mn |
| Dec 31, 2022 | -11.67 Mn |
| Sep 30, 2022 | -13.61 Mn |
| Jun 30, 2022 | -15.87 Mn |
| Mar 31, 2022 | -15.37 Mn |
| Dec 31, 2021 | -15.17 Mn |
| Sep 30, 2021 | -15.45 Mn |
| Jun 30, 2021 | -15.12 Mn |
| Mar 31, 2021 | -14.95 Mn |
| Dec 31, 2020 | -12.64 Mn |
| Sep 30, 2020 | -2.25 Mn |
| Jun 30, 2020 | -9.77 Mn |
| Mar 31, 2020 | -8.66 Mn |
| Dec 31, 2019 | -8.36 Mn |
| Sep 30, 2019 | -59.52 Mn |
| Jun 30, 2019 | -428,000.00 |
| Dec 31, 2018 | -4.83 Mn |
| Sep 30, 2018 | -14.73 Mn |
| Jun 30, 2018 | 3.07 Mn |
| Dec 31, 2017 | -16.25 Mn |
| Sep 30, 2017 | -11.83 Mn |
| Jun 30, 2017 | -13.75 Mn |
| Mar 31, 2017 | -8.32 Mn |
| Sep 30, 2016 | -8.15 Mn |
| Jun 30, 2016 | -10.90 Mn |
| Mar 31, 2016 | -6.71 Mn |
| Dec 31, 2015 | -5.66 Mn |
| Sep 30, 2015 | -5.04 Mn |
| Jun 30, 2015 | -4.75 Mn |
| Mar 31, 2015 | -6.41 Mn |
| Dec 31, 2014 | -8.09 Mn |
| Sep 30, 2014 | -6.28 Mn |
| Jun 30, 2014 | -5.42 Mn |
| Mar 31, 2014 | -4.23 Mn |
| Dec 31, 2013 | -3.54 Mn |
| Sep 30, 2013 | -3.37 Mn |
| Jun 30, 2013 | -811,502.00 |
| Mar 31, 2013 | -1.01 Mn |